Nuvation Bio is trading 5.60% down at $4.46 amid a sharp market-wide sell-off and biotech weakness.
- The XBI biotech sector is down 5.19%, while major indexes are also falling, consistent with pressure on growth stocks.
- November 4 earnings brought a revenue beat and raised guidance, but reports noted an after-hours pullback. That reaction may have added pressure; broader market and sector weakness is the clearer explanation for the November 5 move.